☰

Brian P. Danysh, Ph.D. - Publications

Affiliations: 
2010 Department of Biological Sciences University of Delaware, Newark, DE, United States 
Area:
Molecular Biology
Tree Info Similar researchers PubMed Report error

10/27 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Puli OR, Danysh BP, McBeath E, Sinha DK, Hoang NM, Powell RT, Danysh HE, Cabanillas ME, Cote GJ, Hofmann MC. The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia (New York, N.Y.). 20: 1121-1134. PMID 30265861 DOI: 10.1016/J.Neo.2018.09.003  0.393
2018 Paez-Mayorga J, Chen AL, Kotla S, Tao Y, Abe RJ, He ED, Danysh BP, Hofmann MC, Le NT. Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation. Frontiers in Cardiovascular Medicine. 5: 125. PMID 30238007 DOI: 10.3389/Fcvm.2018.00125  0.355
2016 Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC. Long-Term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget. PMID 27127178 DOI: 10.18632/Oncotarget.9023  0.353
2016 Danysh BP, Cabanillas ME, Hofmann M. Abstract 2933: Long-term BRAF(V600E) inhibition results in a spontaneous KRAS(G12D) mutation and increased epithelial to mesenchymal transition (EMT) in papillary thyroid cancer cells (PTC) Cancer Research. 76: 2933-2933. DOI: 10.1158/1538-7445.Am2016-2933  0.392
2011 Constantinou PE, Danysh BP, Dharmaraj N, Carson DD. Transmembrane mucins as novel therapeutic targets. Expert Review of Endocrinology & Metabolism. 6: 835-848. PMID 22201009 DOI: 10.1586/Eem.11.70  0.34
2011 Danysh BP, Constantinou PE, Lukianova-Hleb E, Broaddus R, Carson DD. Abstract 368: MUC1-targeted gold nanoparticle-based theranostic approach Cancer Research. 71: 368-368. DOI: 10.1158/1538-7445.Am2011-368  0.367
2010 Danysh BP, Patel TP, Czymmek KJ, Edwards DA, Wang L, Pande J, Duncan MK. Characterizing molecular diffusion in the lens capsule. Matrix Biology : Journal of the International Society For Matrix Biology. 29: 228-36. PMID 20026402 DOI: 10.1016/J.Matbio.2009.12.004  0.571
2009 Firtina Z, Danysh BP, Bai X, Gould DB, Kobayashi T, Duncan MK. Abnormal expression of collagen IV in lens activates unfolded protein response resulting in cataract. The Journal of Biological Chemistry. 284: 35872-84. PMID 19858219 DOI: 10.1074/Jbc.M109.060384  0.425
2009 Danysh BP, Duncan MK. The lens capsule. Experimental Eye Research. 88: 151-64. PMID 18773892 DOI: 10.1016/J.Exer.2008.08.002  0.597
2008 Danysh BP, Czymmek KJ, Olurin PT, Sivak JG, Duncan MK. Contributions of mouse genetic background and age on anterior lens capsule thickness. Anatomical Record (Hoboken, N.J. : 2007). 291: 1619-27. PMID 18951502 DOI: 10.1002/Ar.20753  0.537
Low-probability matches (unlikely to be authored by this person)
2021 Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, et al. Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers. 13. PMID 34638434 DOI: 10.3390/cancers13194950  0.281
2014 Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity Hormones and Cancer. 6: 21-36. DOI: 10.1007/S12672-014-0207-9  0.276
2012 Lukianova-Hleb EY, Ren X, Constantinou PE, Danysh BP, Shenefelt DL, Carson DD, Farach-Carson MC, Kulchitsky VA, Wu X, Wagner DS, Lapotko DO. Improved cellular specificity of plasmonic nanobubbles versus nanoparticles in heterogeneous cell systems. Plos One. 7: e34537. PMID 22509318 DOI: 10.1371/Journal.Pone.0034537  0.274
2022 Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale SP, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, et al. Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance. Blood Advances. PMID 36287227 DOI: 10.1182/bloodadvances.2022008447  0.255
2012 Danysh BP, Constantinou PE, Lukianova-Hleb EY, Lapotko DO, Carson DD. The MUC1 Ectodomain: A Novel and Efficient Target for Gold Nanoparticle Clustering and Vapor Nanobubble Generation. Theranostics. 2: 777-87. PMID 22916077 DOI: 10.7150/Thno.4494  0.254
2019 Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, ... Danysh BP, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine. 25: 1415-1421. PMID 31501609 DOI: 10.1038/S41591-019-0561-9  0.25
2019 Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, ... Danysh BP, et al. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine. PMID 31745334 DOI: 10.1038/S41591-019-0698-6  0.24
2019 Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin L, Seventer EEV, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, ... Danysh BP, et al. Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-257  0.237
2023 Khalsa JK, Cha J, Utro F, Naeem A, Murali I, Kuang Y, Vasquez KA, Li L, Tyekucheva S, Fernandes SM, Veronese L, Guieze R, Kandathilparambil Sasi B, Wang Z, Machado JH, ... ... Danysh BP, et al. Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples. Blood. PMID 37146250 DOI: 10.1182/blood.2022016600  0.232
2018 Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis. 7: 23. PMID 29487290 DOI: 10.1038/s41389-017-0015-5  0.219
2022 Noronha A, Belugali Nataraj N, Sang Lee J, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, ... ... Danysh BP, et al. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discovery. PMID 35895872 DOI: 10.1158/2159-8290.CD-22-0111  0.21
2020 Utro F, Rhrissorrakrai K, Levovitz C, Leshchiner I, Martin L, Chen C, Pinto C, Danysh B, Slowik K, Goyal L, Allen R, Broudo MW, Juric D, Getz G, Parida L. Abstract 1509: Estimation of lesion-specific mutation shedding in cfDNA from rapid autopsy study Cancer Research. 80: 1509-1509. DOI: 10.1158/1538-7445.Am2020-1509  0.2
2023 Varkaris A, Fece de la Cruz F, Martin EE, Norden BL, Chevalier N, Kehlmann AM, Leshchiner I, Barnes H, Ehnstrom S, Stavridi AM, Yuan X, Kim JS, Ellis H, Papatheodoridi A, Gunaydin H, ... Danysh BP, et al. Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Cancer Discovery. PMID 37916958 DOI: 10.1158/2159-8290.CD-23-0704  0.196
2021 Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorrakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discovery. PMID 34404686 DOI: 10.1158/2159-8290.CD-21-0702  0.182
2023 Burr R, Leshchiner I, Costantino CL, Blohmer M, Sundaresan T, Cha J, Seeger K, Guay S, Danysh BP, Gore I, Jacobs RA, Slowik K, Utro F, Rhrissorrakrai K, Levovitz C, et al. Germline mutations and developmental mosaicism underlying -mutant lung cancer. Medrxiv : the Preprint Server For Health Sciences. PMID 37808694 DOI: 10.1101/2023.09.28.23296274  0.172
2022 Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, ... ... Danysh BP, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nature Medicine. PMID 36097221 DOI: 10.1038/s41591-022-01959-0  0.148
2023 Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, ... ... Danysh BP, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nature Medicine. PMID 36624313 DOI: 10.1038/s41591-022-02113-6  0.117
Hide low-probability matches.